Boston Scientific Corporation $BSX Shares Sold by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 4.3% during the 3rd quarter, Holdings Channel.com reports. The fund owned 217,282 shares of the medical equipment provider’s stock after selling 9,700 shares during the period. Aristotle Atlantic Partners LLC’s holdings in Boston Scientific were worth $21,213,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC raised its holdings in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Boston Scientific in the second quarter valued at $249,000. SBI Securities Co. Ltd. grew its holdings in Boston Scientific by 31.5% in the second quarter. SBI Securities Co. Ltd. now owns 4,028 shares of the medical equipment provider’s stock valued at $433,000 after purchasing an additional 965 shares during the last quarter. Advisors Capital Management LLC increased its position in shares of Boston Scientific by 46.5% in the second quarter. Advisors Capital Management LLC now owns 6,446 shares of the medical equipment provider’s stock valued at $692,000 after buying an additional 2,046 shares in the last quarter. Finally, Foundations Investment Advisors LLC increased its position in shares of Boston Scientific by 16.1% in the second quarter. Foundations Investment Advisors LLC now owns 4,178 shares of the medical equipment provider’s stock valued at $449,000 after buying an additional 579 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. TD Cowen decreased their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Stifel Nicolaus dropped their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Robert W. Baird cut their target price on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. Finally, Barclays lowered their price target on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $108.00.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.9%

Shares of BSX opened at $69.15 on Friday. Boston Scientific Corporation has a fifty-two week low of $67.56 and a fifty-two week high of $109.50. The company has a market capitalization of $102.61 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.69. The stock has a fifty day moving average of $82.47 and a two-hundred day moving average of $93.29. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The business had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.